Green Tea Polyphenol (−)-Epigallocatechin-3-gallate Inhibits Cyclooxygenase-2 Expression in Colon Carcinogenesis

Guang Peng,† Dan A. Dixon,‡ Stephanie J. Muga,† Theresa J. Smith,† and Michael J. Wargovich†*

†Department of Pathology and Microbiology, School of Medicine, The University of South Carolina, and South Carolina Cancer Center, Columbia, South Carolina
‡Department of Biological Sciences, The University of South Carolina, and South Carolina Cancer Center, Columbia, South Carolina

Tea, one of the most widely consumed beverages worldwide, has been shown to have anti-cancer activity in various cancers including colon cancer. It has been demonstrated that overexpression of the inducible isoform of cyclooxygenase (COX-2) occurs during colon tumorigenesis and inhibition of COX-2 by non-steroidal anti-inflammatory drugs (NSAIDs) is chemopreventive. To determine whether the anti-cancer effect associated with green tea impacted COX-2 expression levels, human colorectal cancer cell lines HT-29 and HCA-7, were treated with (−)-epigallocatechin-3-gallate (EGCG), the most abundant and effective polyphenol in green tea. EGCG significantly inhibited constitutive COX-2 mRNA and protein overexpression. The inhibitory effects of EGCG on signaling pathways controlling COX-2 expression were examined. We observed that EGCG downregulated the ERK1/2 and Akt pathways in colon cancer cells. The effect of EGCG on COX-2 expression resulted in decreased COX-2 promoter activity via inhibition of nuclear factor κB (NF-κB) activation. EGCG also promoted rapid mRNA decay mediated through the COX-2 3′untranslated region (3′UTR). In conclusion, these data suggest that inhibition of COX-2 is a mechanism for the anti-proliferative effect of green tea and emphasizes the role that dietary factors have as anti-cancer agents.

© 2006 Wiley-Liss, Inc.

Key words: EGCG; COX-2; gene expression; NF-κB; MAPKs; colon cancer cells

INTRODUCTION

Colorectal cancer is a leading cause of cancer and cancer-related deaths among both men and women in the United States [1]. Colon carcinogenesis is a multistep process described as a series of tumor suppressor gene inactivation paired with oncogene activation [2]. Considerable experimental evidence demonstrates that dysregulation of cyclooxygenase 2 (COX-2) gene expression occurs in the early stage of colon carcinogenesis, resulting in overexpression of COX-2 in approximately 40% of adenomas and 80% of adenocarcinomas [3]. Data from epidemiological and animal models indicate that non-steroidal anti-inflammatory drugs (NSAIDs), which inhibit COX activity, reduce the relative risk of colon cancer and promote tumor regression [4]. Additionally, genetic evidence establishes an association between COX-2 expression and colon cancer. Adenomatous polyposis coli (APC) mutant mice (Apcc)[1]; develop hundreds of intestinal polyps, whereas Apcc[1] COX-2 double knockout mice have approximately 90% reduction in tumor burden [5]. While demonstrating that inhibition of COX-2 and associated prostaglandin synthesis can limit the development and progression of colon cancer, these findings indicate the efficacy of COX-2 as a viable target for natural product chemoprevention.

COX-2 is an inducible isoform of COX, which is a key enzyme in the biosynthesis of prostaglandins from arachidonic acid (AA). In normal cells, COX-2 expression is low or not observed, but it can rapidly increase in response to various stimuli (growth factors, cytokines, and tumor promoters). It has been well established that COX-2 expression is regulated at both transcriptional level and posttranscriptional level in colon cancer [6–8]. Examination of the COX-2 gene has identified a number of transcription factor

Abbreviations: EGCG, (−)-epigallocatechin-3-gallate; COX-2, cyclooxygenase-2; NF-κB, nuclear factor κB; NSAIDs, non-steroidal anti-inflammatory drugs; 3′UTR, 3′ untranslated region; MAPK, mitogen-activated protein kinase; PBK, phosphatidylinositol 3 kinase; ERK, extracellular signal regulated kinase; RT, room temperature; CMV-β-Gal, β-galactosidase plasmid; CMV, cytomegalovirus; GAPDH, glyceraldehyde 3 phosphate dehydrogenase.

*Correspondence to: Wargovich, South Carolina Cancer Center, 14 Richland Medical Park Drive, Suite 500, Columbia, SC 29203. Received 19 September 2005; revised 13 October 2005; accepted 20 October 2005. DOI 10.1002/mc.20166